Oligonucleotide Synthesis Market

Oligonucleotide Synthesis Market Size (2024-2029):

The Global Oligonucleotide Synthesis Market is expected to grow at a CAGR of 7.3% during the forecast period 2024-2029. The market value was at USD 6.76 billion in 2023, and the value is expected to reach USD 10.32 billion by the end of 2029.

Market Overview:

Oligonucleotides are short pieces of nucleic acids that are blended with the assistance of genetic engineering and enzyme chemistry. These are generally employed in workshops for uses like therapeutic, diagnostics, and also educational, and industrial. These are employed from the start of research and screening through to oligonucleotide synthesis acceptance and drug production. Oligonucleotide synthesis takes place either commercially to offer assistance for different end-users or singly via DNA synthesizers for self-consumption. Nowadays, consecutive enhancements in oligonucleotide synthesis, amplification, and automation have fully revolutionized biological investigation. It is also possible to do the customizations and get the required order online easily and at the needed time. These assistances differ highly by the cost of per base pair, error rates, lengths, throughput, etc.

Market Drivers and Restraints:

Oligonucleotides find remarkable potential in the treatment of various medical concerns. They uplift the advancement of therapeutics as the collapsing genes can be targeted, controlled, silenced, and/or regulated. The industry scenario right now involves traditional players in both the gadgets and services industry with excellent brand recognition and grown distribution passages. The systematic dispensation channels operating in the worldwide oligonucleotide synthesis industry have succored the industry continues on a rise in advancement trajectory. The latest trend shows that the in-house advancement of oligonucleotide influences sales from service providers. This in-house advancement is highly carried out by educational and research institutes. Biopharmaceutical companies have already initiated the creation of oligonucleotides with their own resources or have offered the deal to other organizations in order to keep confidentiality and ease of making. Restricted needs and price constraints nevertheless cannot be tracked and hence result in narrowing down the industry scope. So many significant and rising oligonucleotide makers are growing their industries through collaboration with pharmaceutical makers.

An escalation in the use of artificial oligonucleotides in the industry and in educational research laboratories has led to an escalation in the call for quality developments to curb impurities and expand its effectiveness. Nevertheless, the expenses of purification account for approximately half of the final production expense, and continuous research is right now ongoing to find upgraded techniques to attain the required results – like the introduction of non-chromatographic techniques of purification and so many in-house advanced modifications. The global oligonucleotide synthesis market is deemed to witness restrictions in terms of funding in educational laboratories that may limit the boom in industry revenue. The escalating awareness about the broad variety of uses of oligonucleotide synthesis has assisted the government to fund research activities. Advancements in oligonucleotide synthesis and a surge in research activities in artificial biology are accelerating the boom in the global oligonucleotide synthesis industry. 

Expanding interest in customized medicine is also likely to positively impact the growth of the oligonucleotide synthesis business over the calculated period. Customized medicine provides tailored medical treatment on the basis of individual requirements and preferences of patients. Oligonucleotide synthesis assists in providing customized solutions to ill patients. The advent of anti-sense RNA therapeutics has attained great traction in the biotechnology industry. The high application of customized medicine to treat rare diseases is attainable with oligonucleotide synthesis. With progressions in oligonucleotide synthesis, patients can now be treated and analyzed more proficiently. Hence, a rising focus on customized medicine is estimated to create lucrative opportunities for the players working in the business.

OLIGONUCLEOTIDE SYNTHESIS MARKET REPORT COVERAGE:

Market Segmentation:

Oligonucleotide Synthesis Market - By Product:

• Oligonucleotide-Based Drugs
• Primers
• Probes
• Large-Scale Synthesized Oligos
• Intermediate-Scale Synthesized Oligos
• Linkers & Adaptors

This sector is also predicted to rise at the quickest CAGR throughout the foreseen period because of the escalating call for oligonucleotide-based drugs and the invasion of the latest consumers in the oligodrug advancement stage. Besides, there are a few oligonucleotide-based drugs in the final stages and analysis, and they might be introduced in the next five years that will greatly affect this industry in a positive manner.

Oligonucleotide Synthesis Market - By End-user:

• Academic Research Institutes
• Diagnostic Laboratories
• Pharmaceutical & Biotechnology Companies
• Hospitals

Hospitals contributed the highest revenue compared to all the other sectors within the industry in 2020. The high number of inpatient and outpatient visits in hospitals collaborated with the extreme need for oligonucleotide drugs to boost the call from the extensive patient pool suffering from diseases.

Market Regional Analysis: 

The Global Oligonucleotide Synthesis Market Report includes the segmentation of regions:

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

Asian countries are predicted to escalate as a significant source of high revenue generation throughout the foreseen period. This is high because of the growing awareness and also the popularity of genetic medicine in the population. In 2019, Europe was the topmost industry for share, followed by North America. Furthermore, Europe is predicted to experience the highest CAGR over the prediction period mainly owing to the escalating R&D activities and the mounting number of oligonucleotide-based drugs/therapies being accepted by the FDA.

Market Key Players:

1. Agilent Technologies, Inc. (US)
2. ATDBio Ltd. (UK)
3. Bio-Synthesis, Inc. (US)
4. BioAutomation Corporation (US)
5. LGC Biosearch Technologies (US)
6. Biogen International (US)
7. Sarepta Therapeutics (US)
8. Eurofins Genomics (Germany)
9. Eurogentec (Belgium)
10. GeneDesign, Inc. (Japan)
11. GE Healthcare (US)
12. GenScript, Inc. (US)
13. Integrated DNA Technologies (IDT, US)
14. Nitto Denko Avecia, Inc. (US)

Market Key Developments:

• Dalton Pharma Services has declared the fulfillment of its Oligonucleotide Production Suite. The Oligonucleotide Production Suite comprises the most recent technology that allows small to large-scale production and purification capability of Oligo. Special controls, including environmental (for instance, HEPA-filtered air) and making controls have been executed.
• Biolytic Lab Performance Inc. developed Dr. Oligo 48, a new 48-column rotor synthesizer to enhance overall performance aspects like quality, speed, and price. Biolytic Lab Performance, Inc.